PT-141 dosage, reported strictly as label and trial findings.

Before the details

This page reports numbers, it does not prescribe them. The approved bremelanotide product uses a single dose — 1.75 mg injected just under the skin (subcutaneous), taken only when needed, capped at one dose per 24 hours and eight per month. Earlier studies tested a few other doses while figuring out where to land. The drug clears from the body fairly quickly (a half-life of roughly 2.7 hours), yet the desire effect was measured for up to 24 hours in a brain-imaging study, because the brain effect outlasts the blood level. Everything below is the label and trial record. It recommends no dose for any person; the approved product is prescription-only, and those decisions belong to a prescriber.

PT-141 dosage in the research literature

Reported as findings only, the PT-141 dosage record has a clear center of gravity. The bremelanotide label specifies 1.75 mg subcutaneously, as needed, with no more than one dose per 24 hours and no more than 8 doses per month ^[6]. Phase 2 subcutaneous dose-finding in women studied 0.75, 1.25, and 1.75 mg before the program settled on 1.75 mg ^[6].

Two other dosing contexts appear in the literature and should not be confused with the approved regimen. Early intranasal research in men with erectile dysfunction escalated to roughly 7-20 mg, with a statistically significant erectile response above 7 mg, before the intranasal route was discontinued for pharmacokinetic variability ^[1]. And Phase 1 obesity research in women used subcutaneous doses up to 2.5 mg, up to three times daily for 15 days — a research protocol only, and the source of the weight and caloric-intake observations ^[7]. These are study and label figures. None is a recommendation.

If you are looking for the male-research context specifically, the PT-141 for men page treats the off-label, investigational evidence in full.

PT-141 dosage for women in the RECONNECT trials

For the approved indication, the PT-141 dosage for women is the regimen carried by the RECONNECT trials and the label: 1.75 mg subcutaneous, as needed, taken at least 45 minutes before anticipated sexual activity, capped at one dose per 24 hours and 8 per month ^[6]. That is the exact regimen tested in the two Phase 3 trials that supported approval, across 1,267 premenopausal women with HSDD ^[3].

This is the approved-product label for premenopausal women with HSDD, reported here as a finding — not a protocol for any reader to follow. The approved product is a prescription pharmaceutical, and dosing decisions belong to a prescriber ^[6].

How long PT-141 lasts: half-life and timing

The pharmacokinetics and the felt duration are two different clocks. After subcutaneous administration, median Tmax (time to peak concentration) is about 0.5-1.0 hour, and the terminal half-life is approximately 2.7 hours (range 1.9-4.0 h) per the prescribing information ^[6]. Early intranasal studies reported a similar half-life of 1.85-2.09 hours ^[1].

The desire effect, though, outlasts the blood level: in the controlled fMRI study, MC4R agonism increased sexual desire for up to 24 hours ^[5]. That gap is exactly what a central mechanism predicts — the drug clears, but the circuit effect persists ^[1]. The label's 45-minute pre-activity timing reflects the onset side of that profile ^[6].

PT-141 half-life

The PT-141 half-life is approximately 2.7 hours (range 1.9-4.0 h) after subcutaneous administration, per the bremelanotide prescribing information ^[6]. Supporting pharmacokinetics: volume of distribution about 25.0 L, clearance about 6.5 L/hr, roughly 21% serum protein binding, with excretion 64.8% renal and 22.8% fecal from a radiolabeled dose ^[6]. Metabolism proceeds by hydrolysis of the cyclic-peptide amide bonds and peptidase digestion, and the cyclic lactam structure confers greater stability than linear melanocortin peptides ^[1][6].

What is the PT-141 dosage?

Reported as a finding only: the bremelanotide label specifies 1.75 mg subcutaneously, as needed, with no more than one dose per 24 hours and no more than 8 doses per month ^[6]. This is the approved-product label, not a protocol for any reader to follow.

How much PT-141 should I take?

This site recommends no dose for any individual. The literature and label report 1.75 mg subcutaneous as-needed for the approved HSDD indication in premenopausal women ^[6]; the approved product is prescription-only and dosing decisions belong to a prescriber.

How much PT-141 to inject?

The reported label dose is 1.75 mg subcutaneous as-needed ^[6]; Phase 2 dose-finding studied 0.75, 1.25, and 1.75 mg before settling there ^[6]. These are study and label figures, not a recommendation, and the approved product is a prepared single-dose autoinjector.

What is the PT-141 dosage for women?

For the approved HSDD indication in premenopausal women, the label specifies 1.75 mg subcutaneous as-needed, taken at least 45 minutes before anticipated activity, capped at one dose per 24 hours and 8 per month ^[6]. Reported as a finding, not a protocol.

How do you reconstitute PT-141?

The approved product is a prepared single-dose autoinjector, not a reconstituted preparation ^[6]. Material sold as 'PT-141 research chemical' is for laboratory use only; this site does not provide reconstitution or self-administration instructions and recommends no dose for anyone.

How do you take PT-141?

Per the label, bremelanotide is given subcutaneously (abdomen or thigh) as needed, at least 45 minutes before anticipated sexual activity ^[6]. Reported here as the approved administration route for the approved indication, not as guidance to self-administer.

How often can you take PT-141?

The label limit is no more than one dose per 24 hours and no more than 8 doses per month ^[6]. High-frequency dosing appears only in research protocols — for example the Phase 1 obesity studies (up to three times daily) — not the approved regimen ^[7].